| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Opioid | 24 | 2024 | 51 | 4.650 |
Why?
|
| Morphine | 31 | 2016 | 85 | 3.990 |
Why?
|
| Nicotine | 13 | 2024 | 257 | 3.590 |
Why?
|
| Cocaine | 14 | 2024 | 232 | 3.400 |
Why?
|
| Opioid Peptides | 15 | 2024 | 28 | 3.190 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 5 | 2020 | 17 | 3.130 |
Why?
|
| Conditioning, Operant | 8 | 2017 | 73 | 2.660 |
Why?
|
| Analgesics, Opioid | 13 | 2016 | 197 | 2.240 |
Why?
|
| Reward | 7 | 2019 | 79 | 2.130 |
Why?
|
| Receptors, Opioid, mu | 9 | 2016 | 55 | 2.090 |
Why?
|
| Motor Activity | 12 | 2013 | 418 | 1.920 |
Why?
|
| Mice | 66 | 2024 | 5913 | 1.800 |
Why?
|
| Mice, Inbred C57BL | 29 | 2024 | 1609 | 1.760 |
Why?
|
| Mice, Knockout | 23 | 2024 | 933 | 1.720 |
Why?
|
| Animals | 87 | 2024 | 15081 | 1.610 |
Why?
|
| Behavior, Animal | 10 | 2019 | 314 | 1.400 |
Why?
|
| Drug Tolerance | 19 | 2016 | 40 | 1.390 |
Why?
|
| Quinoxalines | 10 | 1999 | 27 | 1.370 |
Why?
|
| beta-Endorphin | 5 | 2013 | 14 | 1.360 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 10 | 1999 | 137 | 1.250 |
Why?
|
| Narcotics | 8 | 2013 | 32 | 1.240 |
Why?
|
| Nicotinic Agonists | 4 | 2019 | 75 | 1.190 |
Why?
|
| Cocaine-Related Disorders | 3 | 2015 | 85 | 1.150 |
Why?
|
| Cotinine | 3 | 2024 | 43 | 1.130 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2010 | 77 | 1.110 |
Why?
|
| Male | 75 | 2024 | 20025 | 1.050 |
Why?
|
| Dose-Response Relationship, Drug | 22 | 2017 | 1039 | 1.050 |
Why?
|
| Pain Measurement | 16 | 2010 | 171 | 0.970 |
Why?
|
| Enkephalins | 8 | 2013 | 33 | 0.970 |
Why?
|
| Analgesia | 10 | 2014 | 20 | 0.960 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2024 | 52 | 0.920 |
Why?
|
| Ethanol | 3 | 2018 | 192 | 0.870 |
Why?
|
| Narcotic Antagonists | 13 | 2016 | 57 | 0.870 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2020 | 107 | 0.870 |
Why?
|
| Excitatory Amino Acid Antagonists | 6 | 1999 | 99 | 0.840 |
Why?
|
| Buprenorphine | 3 | 2008 | 21 | 0.830 |
Why?
|
| Tobacco Use Disorder | 3 | 2021 | 237 | 0.810 |
Why?
|
| Pituitary Gland | 4 | 2020 | 63 | 0.800 |
Why?
|
| Carbohydrate Dehydrogenases | 7 | 2019 | 14 | 0.800 |
Why?
|
| Motivation | 2 | 2020 | 436 | 0.790 |
Why?
|
| Piperidines | 4 | 2018 | 77 | 0.780 |
Why?
|
| Neuropeptides | 1 | 2021 | 59 | 0.770 |
Why?
|
| Proprotein Convertase 2 | 4 | 2016 | 21 | 0.770 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2020 | 1 | 0.740 |
Why?
|
| Eating | 3 | 2017 | 166 | 0.730 |
Why?
|
| Locomotion | 4 | 2006 | 97 | 0.710 |
Why?
|
| Morphine Dependence | 3 | 2016 | 25 | 0.690 |
Why?
|
| Spatial Behavior | 2 | 2012 | 22 | 0.680 |
Why?
|
| Nociceptors | 5 | 2010 | 32 | 0.660 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 71 | 0.650 |
Why?
|
| Indoles | 2 | 2018 | 158 | 0.650 |
Why?
|
| Alcoholism | 1 | 2021 | 240 | 0.640 |
Why?
|
| Naltrexone | 11 | 2014 | 38 | 0.620 |
Why?
|
| Opioid-Related Disorders | 3 | 2021 | 125 | 0.620 |
Why?
|
| Protein Precursors | 3 | 2013 | 61 | 0.610 |
Why?
|
| Homeostasis | 3 | 2017 | 188 | 0.590 |
Why?
|
| Analgesics | 7 | 1998 | 54 | 0.580 |
Why?
|
| Receptors, Glycine | 4 | 1999 | 7 | 0.580 |
Why?
|
| Corticosterone | 5 | 2019 | 77 | 0.570 |
Why?
|
| Central Nervous System Depressants | 2 | 2018 | 37 | 0.550 |
Why?
|
| Analysis of Variance | 8 | 2019 | 550 | 0.550 |
Why?
|
| Stress, Psychological | 4 | 2014 | 583 | 0.540 |
Why?
|
| Glucocorticoids | 4 | 2019 | 86 | 0.540 |
Why?
|
| Adipose Tissue | 4 | 2019 | 177 | 0.530 |
Why?
|
| Mental Disorders | 1 | 2019 | 309 | 0.520 |
Why?
|
| Rats | 18 | 2024 | 3483 | 0.520 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 73 | 0.510 |
Why?
|
| Cyclic AMP | 1 | 2015 | 131 | 0.500 |
Why?
|
| Dynorphins | 2 | 2011 | 14 | 0.500 |
Why?
|
| Naloxone | 9 | 2016 | 52 | 0.490 |
Why?
|
| Brain | 9 | 2016 | 1346 | 0.490 |
Why?
|
| Dextroamphetamine | 2 | 2013 | 10 | 0.470 |
Why?
|
| Microsomes, Liver | 2 | 2024 | 70 | 0.440 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 730 | 0.420 |
Why?
|
| Smoking | 4 | 2022 | 940 | 0.420 |
Why?
|
| Morphine Derivatives | 1 | 2012 | 2 | 0.420 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 2 | 0.420 |
Why?
|
| Nucleus Accumbens | 2 | 2004 | 82 | 0.410 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 7 | 2019 | 17 | 0.410 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2012 | 26 | 0.400 |
Why?
|
| Female | 16 | 2024 | 20969 | 0.400 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2017 | 1618 | 0.390 |
Why?
|
| Psychomotor Performance | 2 | 2010 | 136 | 0.380 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 3 | 2014 | 7 | 0.380 |
Why?
|
| Humans | 19 | 2024 | 37093 | 0.370 |
Why?
|
| Choice Behavior | 2 | 2013 | 79 | 0.370 |
Why?
|
| Time Factors | 9 | 2013 | 1742 | 0.370 |
Why?
|
| Conditioning, Classical | 1 | 2010 | 61 | 0.350 |
Why?
|
| Adiposity | 4 | 2019 | 154 | 0.330 |
Why?
|
| Excitatory Amino Acid Agonists | 2 | 2001 | 48 | 0.320 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 22 | 0.310 |
Why?
|
| Pain | 4 | 1999 | 251 | 0.290 |
Why?
|
| Injections, Intraventricular | 7 | 2009 | 64 | 0.290 |
Why?
|
| Pro-Opiomelanocortin | 3 | 2013 | 15 | 0.280 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 39 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2023 | 643 | 0.280 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 53 | 0.280 |
Why?
|
| Dizocilpine Maleate | 3 | 1996 | 48 | 0.270 |
Why?
|
| Insulin Resistance | 5 | 2019 | 184 | 0.260 |
Why?
|
| Appetite Regulation | 2 | 2017 | 9 | 0.250 |
Why?
|
| Receptors, Glucocorticoid | 4 | 2016 | 34 | 0.240 |
Why?
|
| Lipolysis | 2 | 2014 | 18 | 0.240 |
Why?
|
| Sex Factors | 2 | 2020 | 898 | 0.220 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 3 | 2013 | 54 | 0.220 |
Why?
|
| Taste Buds | 1 | 2022 | 3 | 0.220 |
Why?
|
| Ageusia | 1 | 2022 | 2 | 0.220 |
Why?
|
| Anxiety | 2 | 2020 | 754 | 0.220 |
Why?
|
| Melatonin | 1 | 2023 | 82 | 0.210 |
Why?
|
| Proprotein Convertase 1 | 3 | 2013 | 11 | 0.210 |
Why?
|
| Hot Temperature | 4 | 2014 | 128 | 0.210 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 61 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2014 | 15 | 0.210 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 2013 | 15 | 0.210 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 103 | 0.210 |
Why?
|
| Genotype | 2 | 2019 | 730 | 0.210 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 143 | 0.210 |
Why?
|
| Drug Interactions | 3 | 2012 | 141 | 0.200 |
Why?
|
| Vasodilator Agents | 1 | 2001 | 56 | 0.200 |
Why?
|
| Neuroimmunomodulation | 1 | 2021 | 13 | 0.200 |
Why?
|
| Oxides | 1 | 2022 | 89 | 0.200 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2021 | 3 | 0.200 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 461 | 0.190 |
Why?
|
| Extracellular Space | 1 | 2001 | 35 | 0.190 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 182 | 0.190 |
Why?
|
| Obesity, Abdominal | 2 | 2018 | 30 | 0.190 |
Why?
|
| Somatostatin | 1 | 2000 | 22 | 0.190 |
Why?
|
| Hyperalgesia | 1 | 2000 | 18 | 0.190 |
Why?
|
| Benzimidazoles | 3 | 2007 | 36 | 0.190 |
Why?
|
| Neuroglia | 1 | 2021 | 124 | 0.190 |
Why?
|
| Mecamylamine | 1 | 2020 | 15 | 0.190 |
Why?
|
| Dopamine | 2 | 2002 | 245 | 0.180 |
Why?
|
| Benzamides | 2 | 2018 | 78 | 0.180 |
Why?
|
| Hepatocytes | 4 | 2010 | 75 | 0.170 |
Why?
|
| Aerosols | 1 | 2019 | 48 | 0.170 |
Why?
|
| Self Administration | 1 | 2019 | 42 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 51 | 0.170 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2014 | 22 | 0.170 |
Why?
|
| Energy Metabolism | 2 | 2017 | 168 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2019 | 76 | 0.170 |
Why?
|
| Association Learning | 2 | 2010 | 30 | 0.170 |
Why?
|
| Neurons | 4 | 2017 | 1175 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 119 | 0.160 |
Why?
|
| Gene Expression Regulation | 6 | 2013 | 1015 | 0.160 |
Why?
|
| Kidney | 1 | 2021 | 337 | 0.160 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1998 | 8 | 0.160 |
Why?
|
| Swimming | 3 | 2010 | 38 | 0.160 |
Why?
|
| Injections, Intraperitoneal | 4 | 2008 | 60 | 0.160 |
Why?
|
| Postural Balance | 1 | 1998 | 32 | 0.150 |
Why?
|
| Cricetulus | 1 | 2018 | 80 | 0.150 |
Why?
|
| CHO Cells | 1 | 2018 | 124 | 0.150 |
Why?
|
| Feeding Behavior | 2 | 2013 | 454 | 0.150 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2017 | 11 | 0.150 |
Why?
|
| Abdominal Fat | 2 | 2014 | 21 | 0.150 |
Why?
|
| Depression | 2 | 2023 | 712 | 0.150 |
Why?
|
| Receptors, Amino Acid | 1 | 1997 | 1 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2018 | 64 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2021 | 646 | 0.150 |
Why?
|
| Obesity | 3 | 2023 | 1067 | 0.150 |
Why?
|
| Water | 1 | 2019 | 296 | 0.140 |
Why?
|
| Formaldehyde | 4 | 1998 | 33 | 0.140 |
Why?
|
| Adolescent | 3 | 2023 | 5363 | 0.140 |
Why?
|
| Extinction, Psychological | 1 | 2017 | 90 | 0.140 |
Why?
|
| Seizures | 2 | 1994 | 68 | 0.140 |
Why?
|
| Sex Characteristics | 2 | 2017 | 230 | 0.140 |
Why?
|
| Adipocytes | 4 | 2018 | 58 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 286 | 0.130 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 37 | 0.130 |
Why?
|
| Receptors, Opioid, delta | 2 | 2014 | 23 | 0.130 |
Why?
|
| Embryonic Stem Cells | 1 | 2015 | 59 | 0.130 |
Why?
|
| Cells, Cultured | 6 | 2017 | 1518 | 0.130 |
Why?
|
| Liver | 3 | 2013 | 479 | 0.130 |
Why?
|
| Neurogenesis | 1 | 2015 | 58 | 0.130 |
Why?
|
| Adipose Tissue, White | 1 | 2014 | 14 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 803 | 0.130 |
Why?
|
| Astrocytes | 1 | 2017 | 255 | 0.130 |
Why?
|
| Stimulation, Chemical | 2 | 2007 | 22 | 0.120 |
Why?
|
| Up-Regulation | 5 | 1992 | 513 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2014 | 118 | 0.120 |
Why?
|
| Reaction Time | 5 | 2008 | 143 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2014 | 149 | 0.120 |
Why?
|
| Endocrine System Diseases | 2 | 2012 | 13 | 0.120 |
Why?
|
| Injections, Spinal | 5 | 1997 | 13 | 0.120 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 33 | 0.110 |
Why?
|
| Antiporters | 1 | 2013 | 10 | 0.110 |
Why?
|
| Aging | 1 | 2017 | 664 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 409 | 0.110 |
Why?
|
| Virulence Factors, Bordetella | 2 | 1991 | 7 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2022 | 617 | 0.100 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 13 | 0.100 |
Why?
|
| Pertussis Toxin | 2 | 1991 | 27 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1371 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2018 | 938 | 0.100 |
Why?
|
| Pyrrolidines | 1 | 2012 | 29 | 0.100 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 48 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 55 | 0.100 |
Why?
|
| Body Weight | 5 | 2013 | 434 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2012 | 118 | 0.100 |
Why?
|
| Body Composition | 1 | 2011 | 162 | 0.090 |
Why?
|
| Mice, Inbred Strains | 3 | 2010 | 116 | 0.090 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 2008 | 13 | 0.090 |
Why?
|
| Oocytes | 3 | 1996 | 146 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2021 | 269 | 0.090 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2010 | 79 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 108 | 0.090 |
Why?
|
| Endocrine System | 1 | 2009 | 11 | 0.090 |
Why?
|
| Opiate Alkaloids | 1 | 2009 | 8 | 0.090 |
Why?
|
| Drug Synergism | 3 | 1999 | 177 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2012 | 308 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 109 | 0.080 |
Why?
|
| Adult | 2 | 2021 | 11712 | 0.080 |
Why?
|
| Kinetics | 5 | 1995 | 708 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2008 | 48 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 80 | 0.080 |
Why?
|
| Brain Chemistry | 3 | 1996 | 140 | 0.080 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2019 | 42 | 0.070 |
Why?
|
| Amphetamine | 1 | 2007 | 16 | 0.070 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2006 | 24 | 0.070 |
Why?
|
| Spinal Cord | 4 | 1992 | 94 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2018 | 1908 | 0.070 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2006 | 7 | 0.070 |
Why?
|
| Proprotein Convertases | 1 | 2006 | 8 | 0.070 |
Why?
|
| Substantia Nigra | 2 | 2004 | 44 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2006 | 18 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 59 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 626 | 0.070 |
Why?
|
| Social Environment | 1 | 2008 | 207 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2006 | 80 | 0.070 |
Why?
|
| Ventral Tegmental Area | 2 | 2002 | 36 | 0.070 |
Why?
|
| Xenopus laevis | 2 | 1996 | 73 | 0.060 |
Why?
|
| Protein Binding | 1 | 2008 | 972 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 174 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 928 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 160 | 0.060 |
Why?
|
| Species Specificity | 3 | 1994 | 245 | 0.060 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 4 | 1991 | 6 | 0.060 |
Why?
|
| Binding, Competitive | 2 | 1996 | 111 | 0.060 |
Why?
|
| Feedback | 1 | 2023 | 53 | 0.060 |
Why?
|
| Cricetinae | 1 | 2003 | 238 | 0.060 |
Why?
|
| Immune System | 1 | 2023 | 41 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 484 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 136 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2019 | 353 | 0.050 |
Why?
|
| Corpus Striatum | 1 | 2004 | 104 | 0.050 |
Why?
|
| Mice, Obese | 2 | 2018 | 40 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 539 | 0.050 |
Why?
|
| Tongue | 1 | 2022 | 11 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 28 | 0.050 |
Why?
|
| RNA Interference | 2 | 2014 | 243 | 0.050 |
Why?
|
| Sucrose | 1 | 2022 | 26 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2003 | 444 | 0.050 |
Why?
|
| Taste | 1 | 2022 | 41 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 239 | 0.050 |
Why?
|
| Pyridines | 1 | 2022 | 116 | 0.050 |
Why?
|
| Mifepristone | 2 | 2016 | 34 | 0.050 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2021 | 11 | 0.050 |
Why?
|
| Microdialysis | 1 | 2001 | 18 | 0.050 |
Why?
|
| Apomorphine | 1 | 2001 | 13 | 0.050 |
Why?
|
| Hypogonadism | 2 | 2012 | 21 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2001 | 30 | 0.050 |
Why?
|
| Spironolactone | 1 | 2021 | 39 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2013 | 1207 | 0.050 |
Why?
|
| Gene Expression | 2 | 2008 | 674 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 15 | 0.040 |
Why?
|
| Glycine | 1 | 1999 | 47 | 0.040 |
Why?
|
| Dietary Fats | 2 | 2011 | 119 | 0.040 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 4 | 1992 | 17 | 0.040 |
Why?
|
| Hypothalamus | 2 | 2010 | 129 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2019 | 68 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 129 | 0.040 |
Why?
|
| Hippocampus | 1 | 2001 | 561 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 1999 | 103 | 0.040 |
Why?
|
| Hydroxylamines | 1 | 2017 | 4 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 11 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 70 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 58 | 0.040 |
Why?
|
| Chemistry | 1 | 1997 | 17 | 0.040 |
Why?
|
| Tail | 1 | 1997 | 6 | 0.040 |
Why?
|
| Fetus | 1 | 2017 | 105 | 0.040 |
Why?
|
| Chemical Phenomena | 1 | 1997 | 54 | 0.040 |
Why?
|
| Receptors, AMPA | 1 | 1997 | 56 | 0.040 |
Why?
|
| Microinjections | 1 | 1996 | 57 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 1996 | 66 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2017 | 128 | 0.040 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 1996 | 28 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 2016 | 14 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 343 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1996 | 136 | 0.030 |
Why?
|
| Adipogenesis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Drug Implants | 2 | 2013 | 21 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 11 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 45 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 433 | 0.030 |
Why?
|
| Enkephalin, Methionine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2014 | 10 | 0.030 |
Why?
|
| Eosinophils | 1 | 2014 | 20 | 0.030 |
Why?
|
| Breeding | 1 | 1994 | 21 | 0.030 |
Why?
|
| Xenopus | 1 | 1995 | 48 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 29 | 0.030 |
Why?
|
| Etorphine | 1 | 2014 | 1 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2014 | 16 | 0.030 |
Why?
|
| Diazepam | 1 | 2014 | 12 | 0.030 |
Why?
|
| Ion Channels | 1 | 2014 | 71 | 0.030 |
Why?
|
| Binding Sites | 2 | 1993 | 651 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 107 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 168 | 0.030 |
Why?
|
| Piperazines | 1 | 2014 | 111 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2013 | 22 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2013 | 28 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2026 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1994 | 150 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 10 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2013 | 39 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2019 | 517 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1992 | 53 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2015 | 587 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 51 | 0.030 |
Why?
|
| United States | 1 | 2021 | 4223 | 0.020 |
Why?
|
| Energy Intake | 1 | 2011 | 170 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 435 | 0.020 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tetrodotoxin | 1 | 2010 | 22 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2010 | 17 | 0.020 |
Why?
|
| Biophysics | 1 | 2010 | 37 | 0.020 |
Why?
|
| Reference Values | 1 | 1990 | 212 | 0.020 |
Why?
|
| Enkephalin, Leucine | 1 | 1989 | 5 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 184 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2010 | 223 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 448 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 1354 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 306 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2008 | 65 | 0.020 |
Why?
|
| Carbenoxolone | 1 | 2008 | 10 | 0.020 |
Why?
|
| Deoxyglucose | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 91 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 859 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 623 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 68 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 176 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 523 | 0.020 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2006 | 2 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2006 | 2 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2006 | 6 | 0.020 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2006 | 25 | 0.020 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2006 | 14 | 0.020 |
Why?
|
| Insulin | 1 | 2008 | 236 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 207 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 173 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 893 | 0.010 |
Why?
|
| Glucose | 1 | 2005 | 230 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 677 | 0.010 |
Why?
|
| Injections | 1 | 2002 | 35 | 0.010 |
Why?
|
| Neostriatum | 1 | 2002 | 26 | 0.010 |
Why?
|
| Phenotype | 1 | 2005 | 689 | 0.010 |
Why?
|
| Limbic System | 1 | 2002 | 25 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 578 | 0.010 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 1992 | 7 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2002 | 124 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 1992 | 25 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1992 | 35 | 0.010 |
Why?
|
| Methadone | 1 | 1992 | 19 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1992 | 105 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 133 | 0.010 |
Why?
|
| Receptors, sigma | 1 | 1991 | 15 | 0.010 |
Why?
|